机构：[1]School of Traditional Chinese Medicine and 2School of Public Health, Southern Medical University, Guangzhou,Guangdong 510515[3]Guangdong Second Provincial General Hospital, Guangzhou, Guangdong 510317[4]Department ofOncology, Dongguan People's Hospital, Dongguan, Guangdong 523059[5]Department of Cardiology, The Second AffiliatedHospital of Guangzhou Medical University, Guangzhou, Guangdong 510260[6]HKBU Shenzhen ResearchInstitute and Continuing Education, Shenzhen, Guangdong 518057, P.R. China
Alda‑1, an aldehyde dehydrogenase 2 (ALDH2) agonist, has been demonstrated to reduce injury caused by acute myocardial infarction (MI) and ischemia/reperfusion. The present study aimed to investigate whether oral administration of Alda‑1 improved long‑term survival of rats with chronic heart failure (CHF) post‑MI. MI model rats treated daily with Alda‑1 exhibited an increase in 20‑week survival rate compared with untreated MI rats. Alda‑1 treatment decreased the heart weight/body weight ratio, collagen volume, left ventricular (LV) internal diameter at the end of diastole and LV internal diameter at the end of systole, while increasing LV ejection fraction with evident LV fractional shortening. Myocardial cell apoptosis index, the activity of caspase‑3 and the expression of cleaved‑caspase‑3 were also reduced by Alda‑1 treatment. The protective effects of Alda‑1 were associated with reduced 4‑hydroxynonenal accumulation. The results of the present study revealed that the long‑term treatment with Alda‑1 prevented the progression of ventricular remodeling and improved the long‑term survival of rats with CHF post‑MI.
基金：
The National Natural Science Foundation of China (grant nos. 81673805, 81373575, 81673949 and 81601779), The Guangdong Natural Science Foundation (grant nos. 2014A030313495 and 2014A030310210), The Science and Technology Planning Project of Guangdong Province (grant nos. 2014A020221013 and 2014A020221059), The Science Technology and Innovation Committee of Shenzhen (grant no. JCYJ20150630164505508), Planned Science Technology Project of Guangzhou (201804010064), Medical Science and Technology Research Project of Guangdong Province (grant no. A2016029) and The Traditional Chinese Medicine Bureau of Guangdong Province (grant no. 20161260 and 20162002).
第一作者机构：[1]School of Traditional Chinese Medicine and 2School of Public Health, Southern Medical University, Guangzhou,Guangdong 510515
共同第一作者：
通讯作者：
通讯机构：[1]School of Traditional Chinese Medicine and 2School of Public Health, Southern Medical University, Guangzhou,Guangdong 510515[5]Department of Cardiology, The Second AffiliatedHospital of Guangzhou Medical University, Guangzhou, Guangdong 510260[6]HKBU Shenzhen ResearchInstitute and Continuing Education, Shenzhen, Guangdong 518057, P.R. China[*1]School of Traditional Chinese Medicine, Southern Medical University, 1838 Guangzhou Dadaobei Road, Guangzhou, Guangdong 510515, P.R. China
推荐引用方式(GB/T 7714)：
Hua Yue,Chen Hongmei,Zhao Xinyun,et al.Alda‑1, an aldehyde dehydrogenase‑2 agonist, improves long‑term survival in rats with chronic heart failure following myocardial infarction.[J].MOLECULAR MEDICINE REPORTS.2018,18(3):3159-3166.doi:10.3892/mmr.2018.9309.
APA：
Hua Yue,Chen Hongmei,Zhao Xinyun,Liu Min,Jin Wen...&Zhou Yingchun.(2018).Alda‑1, an aldehyde dehydrogenase‑2 agonist, improves long‑term survival in rats with chronic heart failure following myocardial infarction..MOLECULAR MEDICINE REPORTS,18,(3)
MLA：
Hua Yue,et al."Alda‑1, an aldehyde dehydrogenase‑2 agonist, improves long‑term survival in rats with chronic heart failure following myocardial infarction.".MOLECULAR MEDICINE REPORTS 18..3(2018):3159-3166
